Literature DB >> 11157902

Sources of variation in studies of the early bactericidal activity of antituberculosis drugs.

F Sirgel1, A Venter, D Mitchison.   

Abstract

The early bactericidal activity (EBA) of antituberculosis drugs can be measured as the daily fall in cfu counts of Mycobacterium tuberculosis in sputum, usually during the first 2 days of treatment. In studies of low potency drugs, it is necessary to compare the treated group of patients with a group who receives no chemotherapy (Nil group). Over the past 10 years, five Nil groups of between five and 13 patients have been studied in Cape Town and two Nil groups in Hong Kong. There was a suggestion of an increase in variation within the Cape Town groups, as shown by a regression of variance size against study date (P = 0.06), which could not be attributed to technical causes. It might indicate increasing host resistance in the Western Cape epidemic of tuberculosis. Since the weighted mean of all Nil groups at Cape Town was 0.00036, very close to zero, it would seem safe to test means of treated groups against zero thus increasing precision and avoiding ethical problems in delaying treatment. In contrast to Nil groups, the variation found in five groups who received 300 mg isoniazid daily (INH 300) was uniform and homoscedastic, possibly because the additional variation was caused mainly by individual differences in plasma isoniazid concentrations and patient body weights. The mean EBA in the INH 300 series was 0.575 with 95% confidence limits of 0.515 and 0.636.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157902     DOI: 10.1093/jac/47.2.177

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Alternative strategies for proof-of-principle studies of antibacterial agents.

Authors:  Axel Dalhoff; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

2.  Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.

Authors:  Michael A Lyons
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

3.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12

Review 4.  Assessment of treatment response in tuberculosis.

Authors:  Neesha Rockwood; Elsa du Bruyn; Thomas Morris; Robert J Wilkinson
Journal:  Expert Rev Respir Med       Date:  2016-03-31       Impact factor: 3.772

5.  Differences in EBA in the first two days of standard anti-tuberculosis treatment in different geographic regions.

Authors:  Charles M Bark; Phineas Gitta; John L Johnson
Journal:  Int J Tuberc Lung Dis       Date:  2014-08       Impact factor: 2.373

6.  Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

Authors:  Mathias W R Pletz; Andres De Roux; Andreas Roth; Karl-Heinz Neumann; Harald Mauch; Hartmut Lode
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

7.  Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis.

Authors:  R Brindle; J Odhiambo; D Mitchison
Journal:  BMC Pulm Med       Date:  2001       Impact factor: 3.317

8.  A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations.

Authors:  Oskar Clewe; Sebastian G Wicha; Corné P de Vogel; Jurriaan E M de Steenwinkel; Ulrika S H Simonsson
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

9.  Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.

Authors:  Alan Faraj; Robin J Svensson; Andreas H Diacon; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

10.  Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis.

Authors:  R J Svensson; Ush Simonsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.